MedTrace Logo

Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure

NCT03500731 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2026-01-13

No results posted yet for this study

Summary

The purpose of this study is to determine whether a lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, allowing to proceed to BMT, to restore hematologic function.

Conditions

Interventions

BIOLOGICAL

CD3/CD19 negative hematopoietic stem cells

Negative selection for CD3/CD19 will be performed on CliniMACS® depletion device and given at time no less than 8 weeks post lung transplantation

DRUG

Rituximab

Transplantation Conditioning

DRUG

Alemtuzumab

Transplantation Conditioning

DRUG

Fludarabine

Transplantation Conditioning

DRUG

Thiotepa

Transplantation Conditioning

DRUG

G-CSF

Transplantation conditioning

DRUG

Hydroxyurea

Transplantation Conditioning

Sponsors & Collaborators

  • Paul Szabolcs

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-19
Primary Completion
2027-12-31
Completion
2028-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03500731 on ClinicalTrials.gov